Related Experiment Video

Updated: Aug 16, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

[The molecular basis and in vitro determination of multiple resistance to cytostatic agents]

J Krejsek1, O Kopecký

  • 1II. interní klinika LF UK, Hradec Králové.

Vnitrni Lekarstvi
|August 1, 1995
PubMed

Insights

Chemotherapy resistance in cancer is often caused by P-glycoprotein (P-170), which removes drugs from tumor cells. Assessing P-170 expression and drug sensitivity in leukemia cells offers a promising approach for personalized treatment.

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Cancer therapies often use non-selective cytotoxic or cytostatic drugs.
  • Tumor cell resistance mechanisms can reduce treatment efficacy.
  • P-glycoprotein (P-170) expression is a key factor in multidrug resistance (MDR).

Purpose of the Study:

  • To investigate the role of P-glycoprotein (P-170) in multidrug resistance (MDR) in malignant diseases.
  • To explore the assessment of P-170 expression in leukaemic cells.
  • To evaluate the potential of in vitro drug sensitivity testing for leukemia treatment.

Main Methods:

  • Immunochemical assessment of P-glycoprotein (P-170) expression on leukaemic cells.
  • Utilizing flow cytometry for P-170 detection.
  • In vitro sensitivity testing of leukaemic cells against clinically used cytostatics.

Main Results:

  • P-glycoprotein (P-170) actively extrudes cytotoxic substances from cells, leading to multidrug resistance (MDR).
  • P-170 expression can be quantified on leukaemic cells using immunochemical methods and flow cytometry.
  • In vitro assessment of leukaemic cell sensitivity to cytostatics is a promising diagnostic procedure.

Conclusions:

  • P-glycoprotein (P-170) mediated drug efflux is a critical mechanism of multidrug resistance (MDR) in cancer.
  • Flow cytometry provides a viable method for assessing P-170 expression in leukemia.
  • In vitro drug sensitivity testing holds significant potential for optimizing chemotherapy regimens in leukemia patients.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...